The Age Related Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

“Age Related Macular Degeneration Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Age Related Macular Degeneration Market.

Some of the key takeaways from the Age Related Macular Degeneration Pipeline Report:

• Companies across the globe are diligently working toward developing novel Age Related Macular Degeneration treatment therapies with a considerable amount of success over the years. 
• Age Related Macular Degeneration companies working in the treatment market are Avirmax Inc, Ripple Therapeutics, Innovent Biologics (Suzhou) Co. Ltd, ONL Therapeutics, Shanghai Biomabs Pharmaceutical Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sylentis, S.A, UNITY Biotechnology, Metagone Biotech Inc., RemeGen Co., Ltd, Sam Chun Dang Pharm. Co. Ltd., Zhaoke Ophthalmology Pharmaceutical Ltd., Sinocelltech, and others, are developing therapies for the Age Related Macular Degeneration treatment 

• Emerging Age Related Macular Degeneration therapies in the different phases of clinical trials are- ABI-210, ABI-220, RTC-1020, ABI-112, IBI-333, ONL-1204, CMAB818, IBI-302, SYL1801, UBX1325, MG-O-1002, RC28-E, SCD411, TAB014, SCT510A, and others are expected to have a significant impact on the Age Related Macular Degeneration market in the coming years.   
• In March 2023, RemeGen Co., Ltd. initiated a randomized, double-masked, multicenter studycomparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dualblockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.
• In June 2022, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. initiated a Phase III,randomized, multicenter, doubled-blind clinical trial comparing the efficacy and safety of TAB014 and Lucentis inneovascular age-related macular degeneration (nAMD) patients
• On March 9, 2022, the Group entered into a supplemental agreement with TOT BIOPHARM, pursuant to which ZhaokeGuangzhou will have full control and responsibility in the execution of clinical trials and the ultimate decision-makingpower in the development and commercialization of TAB014 in China, Hong Kong and Macau

Age Related Macular Degeneration Overview

The eye condition known as age-related macular degeneration (AMD) can cause central vision impairment. The macula, the area of the eye that regulates crisp, straight-ahead vision, is harmed by aging. The macula is a component of the retina, which is the back of the eye’s light-sensitive tissue.

Get a Free Sample PDF Report to know more about Age Related Macular Degeneration Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-pipeline-insight

Emerging Age Related Macular Degeneration Drugs Under Different Phases of Clinical Development Include:

• ABI-210: Avirmax Inc
• ABI-220: Avirmax Inc
• RTC-1020: Ripple Therapeutics
• ABI-112: Avirmax Inc
• IBI-333: Innovent Biologics (Suzhou) Co. Ltd
• ONL-1204: ONL Therapeutics
• CMAB818: Shanghai Biomabs Pharmaceutical Co., Ltd.
• IBI-302: Innovent Biologics (Suzhou) Co. Ltd.
• SYL1801: Sylentis, S.A
• UBX1325: UNITY Biotechnology
• MG-O-1002: Metagone Biotech Inc.
• RC28-E: RemeGen Co., Ltd
• SCD411: Sam Chun Dang Pharm. Co. Ltd.
• TAB014: Zhaoke Ophthalmology Pharmaceutical Ltd.
• SCT510A: Sinocelltech

Age Related Macular Degeneration Pipeline Therapeutics Assessment

• Age Related Macular Degeneration Assessment by Product Type
• Age Related Macular Degeneration By Stage and Product Type
• Age Related Macular Degeneration Assessment by Route of Administration
• Age Related Macular Degeneration By Stage and Route of Administration
• Age Related Macular Degeneration Assessment by Molecule Type
• Age Related Macular Degeneration by Stage and Molecule Type

DelveInsight’s Age Related Macular Degeneration Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Age Related Macular Degeneration product details are provided in the report. Download the Age Related Macular Degeneration pipeline report to learn more about the emerging Age Related Macular Degeneration therapies

Some of the key companies in the Age Related Macular Degeneration Therapeutics Market include:

Key companies developing therapies for Age Related Macular Degeneration are – Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Evergreen Therapeutics, Alkeus Pharmaceuticals, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, and others.

Age Related Macular Degeneration Pipeline Analysis:

The Age Related Macular Degeneration pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Age Related Macular Degeneration with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Age Related Macular Degeneration Treatment.
• Age Related Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Age Related Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Age Related Macular Degeneration market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Age Related Macular Degeneration drugs and therapies

Age Related Macular Degeneration Pipeline Market Drivers

• The Rise in the prevalence of Age Related Macular Degeneration (AMD), increasing Research and Developmental Activities are some of the important factors that are fueling the Age Related Macular Degeneration Market.

Age Related Macular Degeneration Pipeline Market Barriers

• However, poor in the quality of care, poor prognosis and lack of efficacy resulting in persistently active disease, morbidity Related to the Disease and other factors are creating obstacles in the Age Related Macular Degeneration Market growth.

Scope of Age Related Macular Degeneration Pipeline Drug Insight    

• Coverage: Global
• Key Age Related Macular Degeneration Companies: Avirmax Inc, Ripple Therapeutics, Innovent Biologics (Suzhou) Co. Ltd, ONL Therapeutics, Shanghai Biomabs Pharmaceutical Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sylentis, S.A, UNITY Biotechnology, Metagone Biotech Inc., RemeGen Co., Ltd, Sam Chun Dang Pharm. Co. Ltd., Zhaoke Ophthalmology Pharmaceutical Ltd., Sinocelltech, and others
• Key Age Related Macular Degeneration Therapies: ABI-210, ABI-220, RTC-1020, ABI-112, IBI-333, ONL-1204, CMAB818, IBI-302, SYL1801, UBX1325, MG-O-1002, RC28-E, SCD411, TAB014, SCT510A, and others
• Age Related Macular Degeneration Therapeutic Assessment: Age Related Macular Degeneration current marketed and Age Related Macular Degeneration emerging therapies
• Age Related Macular Degeneration Market Dynamics: Age Related Macular Degeneration market drivers and Age Related Macular Degeneration market barriers 

Request for Sample PDF Report for Age Related Macular Degeneration Pipeline Assessment and clinical trials

Table of Contents

1. Age Related Macular Degeneration Report Introduction

2. Age Related Macular Degeneration Executive Summary

3. Age Related Macular Degeneration Overview

4. Age Related Macular Degeneration- Analytical Perspective In-depth Commercial Assessment

5. Age Related Macular Degeneration Pipeline Therapeutics

6. Age Related Macular Degeneration Late Stage Products (Phase II/III)

7. Age Related Macular Degeneration Mid Stage Products (Phase II)

8. Age Related Macular Degeneration Early Stage Products (Phase I)

9. Age Related Macular Degeneration Preclinical Stage Products

10. Age Related Macular Degeneration Therapeutics Assessment

11. Age Related Macular Degeneration Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Age Related Macular Degeneration Key Companies

14. Age Related Macular Degeneration Key Products

15. Age Related Macular Degeneration Unmet Needs

16 . Age Related Macular Degeneration Market Drivers and Barriers

17. Age Related Macular Degeneration Future Perspectives and Conclusion

18. Age Related Macular Degeneration Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services